PLoS ONE (Jan 2013)

Direct diabetes-related costs in young patients with early-onset, long-lasting type 1 diabetes.

  • Christina Bächle,
  • Andrea Icks,
  • Klaus Straßburger,
  • Marion Flechtner-Mors,
  • Andreas Hungele,
  • Peter Beyer,
  • Kerstin Placzek,
  • Ulrich Hermann,
  • Andrea Schumacher,
  • Markus Freff,
  • Anna Stahl-Pehe,
  • Reinhard W Holl,
  • Joachim Rosenbauer,
  • DPV Initiative and the German BMBF Competence Network Diabetes Mellitus

DOI
https://doi.org/10.1371/journal.pone.0070567
Journal volume & issue
Vol. 8, no. 8
p. e70567

Abstract

Read online

OBJECTIVE: To estimate diabetes-related direct health care costs in pediatric patients with early-onset type 1 diabetes of long duration in Germany. RESEARCH DESIGN AND METHODS: Data of a population-based cohort of 1,473 subjects with type 1 diabetes onset at 0-4 years of age within the years 1993-1999 were included (mean age 13.9 (SD 2.2) years, mean diabetes duration 10.9 (SD 1.9) years, as of 31.12.2007). Diabetes-related health care services utilized in 2007 were derived from a nationwide prospective documentation system (DPV). Health care utilization was valued in monetary terms based on inpatient and outpatient medical fees and retail prices (perspective of statutory health insurance). Multiple regression models were applied to assess associations between direct diabetes-related health care costs per patient-year and demographic and clinical predictors. RESULTS: Mean direct diabetes-related health care costs per patient-year were €3,745 (inter-quartile range: 1,943-4,881). Costs for glucose self-monitoring were the main cost category (28.5%), followed by costs for continuous subcutaneous insulin infusion (25.0%), diabetes-related hospitalizations (22.1%) and insulin (18.4%). Female gender, pubertal age and poor glycemic control were associated with higher and migration background with lower total costs. CONCLUSIONS: Main cost categories in patients with on average 11 years of diabetes duration were costs for glucose self-monitoring, insulin pump therapy, hospitalization and insulin. Optimization of glycemic control in particular in pubertal age through intensified care with improved diabetes education and tailored insulin regimen, can contribute to the reduction of direct diabetes-related costs in this patient group.